CanTreatCOVID Clinical Trial
Summary
CanTreatCOVID is a national community-based clinical trial investigating drug treatment for adults who get COVID-19.
The purpose of this study is:
1. To identify safe and affordable medications for COVID patients at home and in community care settings that help people have fewer symptoms and feel better faster.
2. To find effective medications that prevent post-COVID condition. This condition, also known as long COVID, includes symptoms that impact a person’s everyday functioning 3 months after the start of their COVID-19 infection.
3. To improve how we care for COVID-19 patients at home and in community settings in Canada and around the world.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 100
Inclusion criteria:
Individuals who:
1) Have a positive COVID-19 test (RAT or PCR) and are within 5 days of symptoms onset
AND are
2) a) Adults aged 50+ years OR b) Adults aged between 18-49 years with 1 or more chronic high-risk medical conditions (for example, diabetes, chronic kidney disease, liver, heart, or respiratory disease to name a few)
Exclusion criteria:
Individuals are not eligible to participate if they:
1) Are admitted to a hospital or stayed in an emergency department for more than 24 hours due to COVID-19.
2) Are already participating in a clinical trial of a drug to treat a COVID-19 infection.
3) Were previously enrolled in the CanTreatCOVID trial.
4) Are unable to provide informed consent, or their caregiver is unable to give informed consent on their behalf.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Email: info@CanTreatCOVID.org
Principal investigator:
Kerry McBrien
Clinical trial:
Yes
REB-ID:
REB22-1061